Dotmatics

Dotmatics Partners with Databricks to Advance Scientific Intelligence in Life Sciences

Dotmatics has partnered with Databricks to enhance scientific intelligence in life sciences by integrating Dotmatics’ Luma™ Scientific Intelligence Platform—supported by products like GraphPad Prism and Geneious—with Databricks’ data intelligence capabilities, enabling life science researchers to unify, analyze, and share large volumes of complex scientific data across various therapeutic discovery modalities such as antibody engineering, CAR-T, and CRISPR, thereby accelerating drug discovery and fostering a new paradigm in biopharmaceutical R&D.

The strategic partnership between Dotmatics and Databricks combines Dotmatics’ expertise in scientific software with Databricks' data intelligence capabilities. This collaboration aims to advance scientific discovery by leveraging the Dotmatics Luma™ Scientific Intelligence Platform, which is built on the Databricks Data Intelligence Platform. Luma enables life science organizations to unify and analyze large volumes of scientific data, driving deeper insights and accelerating discoveries.

Dotmatics Luma aggregates scientific data into intelligent structures to support the Make-Test-Decide cycle across various therapeutic discovery modalities. The platform is supported by Dotmatics’ scientific products, including GraphPad® Prism, Geneious®, SnapGene®, and Protein Metrics.

By integrating Databricks’ ability to manage large, complex datasets with Dotmatics’ life sciences expertise, the partnership aims to provide researchers with faster, scalable pathways to deliver transformative therapeutics. This collaboration is positioned as a foundational pillar for a new paradigm in drug discovery.

Michael Sanky, VP of Healthcare & Life Sciences at Databricks, highlighted the importance of the partnership, noting that Dotmatics Luma exemplifies the transformative potential of building on Databricks and its adoption among the biopharmaceutical community.

Dotmatics recently launched the first of its Luma Multimodal R&D Solutions, focusing on antibody and protein engineering. The platform will also support other therapeutic modalities, including CAR-T cell discovery, siRNA, antibody-drug conjugates (ADCs), CRISPR therapeutics, and vaccine discovery.

Luma, leveraging Databricks' unified data experience, allows scientists to share and analyze data globally within an open ecosystem. Kalim Saliba, Chief Product Officer at Dotmatics, emphasized that joining the Databricks Built On Partner Program enables Dotmatics customers to develop modern Luma applications using common design patterns, improving efficiency and accuracy for data-driven insights.

The partnership aims to provide a unified, scalable, and open data platform for scientific research organizations, enabling them to stay ahead in data science, bench science, and AI-driven insights.

Dotmatics and Databricks will host a webinar titled “Building Breakthroughs: Harnessing Data and AI for Innovation” on Wednesday, December 18 at 12 noon ET. Michael Sanky and Kalim Saliba will discuss how the partnership can transform data-driven discovery.

About Dotmatics

Dotmatics is a leader in R&D scientific software, connecting science, data, and decision-making. Its enterprise R&D platform and applications drive efficiency and accelerate innovation for over 2 million scientists and 10,000 customers worldwide. Dotmatics has a global team of more than 800 people, with offices and R&D teams in over 180 countries. Since 2017, Dotmatics has made 14 acquisitions. The company’s principal office is in Boston, with 14 offices globally. Dotmatics is backed by Insight Partners, a global venture capital and private equity firm investing in high-growth technology and software companies. Learn more at https://www.dotmatics.com/.

Media Contacts

Cory Edwards Vice President, Corporate Communications Dotmatics media@dotmatics.com